Why the study?
While LMNA gene variants are classically linked to familial partial lipodystrophy type 2, certain mutations such as p.Arg349Trp cause severe multisystemic phenotypes that mimic congenital generalized lipodystrophy. Delineating the distinct syndromic expression of the LMNA p.Arg349Trp variant is needed to facilitate early recognition and guide cardiovascular and renal surveillance.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Early phenotypic and molecular recognition of the LMNA p.Arg349Trp multisystem progeroid syndrome is critical to initiate aggressive cardiovascular and renal surveillance before rapid progression to fatal arrhythmias and heart failure.
Background Variants in the LMNA gene are classically associated with familial partial lipodystrophy type 2 (FPLD2/Dunnigan syndrome). However, certain mutations produce severe multisystemic phenotypes that may mimic congenital generalized lipodystrophy (CGL). This case adds to the literature by delineating the distinct syndromic expression of the LMNA p.Arg349Trp variant and underscoring the need for early recognition to guide cardiovascular and renal surveillance. Clinical Findings A 41‐year‐old woman presented to a specialized diabetes clinic serving low‐income populations with severe lipoatrophy of the face and limbs, relative preservation of truncal adiposity, refractory diabetes, severe hypertriglyceridemia, arterial hypertension, and heart failure. Due to the pattern of lipodystrophy, severe systemic involvement, and absence of compensatory cervicofacial fat accumulation, CGL (Berardinelli–Seip syndrome) was initially suspected. Diagnoses, Interventions and Outcomes Next‐generation sequencing identified a heterozygous pathogenic LMNA variant, c.1045C>T (p.Arg349Trp). At baseline, the patient presented with established proteinuric nephropathy, severe hypertriglyceridemia, and cardiovascular disease. Following multidisciplinary care and an optimized pharmacological protocol, transient improvement in metabolic and glycemic profiles was achieved. However, despite good therapeutic response, socioeconomic barriers disrupted access to high‐cost medications, and she deteriorated to cardiovascular and hepatic failure, dying from cardiogenic shock and sepsis of abdominal origin in less than 2 years of follow‐up. Conclusion This case highlights the high clinical severity of the LMNA p.Arg349Trp variant. Recognizing it as a distinct syndromic entity is crucial to prevent diagnostic delays, enabling timely cardiovascular and renal surveillance, particularly in resource‐limited settings where treatment interruptions can have fatal consequences.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2026) conducted a case report in Atypical familial partial lipodystrophy / Multisystem progeroid syndrome (MSPS) with heterozygous LMNA p.Arg349Trp variant (n=1). Heterozygous LMNA c.1045C>T (p.Arg349Trp) variant was evaluated on Clinical progression and mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: